Engineering broadly neutralizing antibodies for HIV prevention and therapy

Advanced Drug Delivery Reviews

Volumn 103, Issue , 2016, Pages 157-173

  Hua, Casey K ^a   Ackerman, Margaret E ^a,b  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b DARTMOUTH COLLEGE   (United States)

Author keywords

Antibody; Effector function; HIV; Neutralization; Prevention; Therapy

Indexed keywords

GENE TRANSFER; PHARMACOKINETICS;

ANTI-HIV ACTIVITY; ANTIVIRAL ACTIVITIES; BIODISTRIBUTIONS; GAINING MOMENTUM; NEUTRALIZATION; NEUTRALIZING ANTIBODIES; PREVENTION; THERAPY;

ANTIBODIES;

ANTIRETROVIRUS AGENT; CYCLOSPORIN; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; IBALIZUMAB; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G1; LENTIVIRUS VECTOR; MICROBICIDE; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; NEUTRALIZING ANTIBODY 10-1074; NEUTRALIZING ANTIBODY 101074; NEUTRALIZING ANTIBODY 10E8; NEUTRALIZING ANTIBODY 2F5; NEUTRALIZING ANTIBODY 2G12; NEUTRALIZING ANTIBODY 3BNC117; NEUTRALIZING ANTIBODY 4E10; NEUTRALIZING ANTIBODY B12; NEUTRALIZING ANTIBODY F105; NEUTRALIZING ANTIBODY KD 247; NEUTRALIZING ANTIBODY M9; NEUTRALIZING ANTIBODY NIH45-46; NEUTRALIZING ANTIBODY P2G12; NEUTRALIZING ANTIBODY PG16; NEUTRALIZING ANTIBODY PG9; NEUTRALIZING ANTIBODY PGT121; NEUTRALIZING ANTIBODY VRC01; NEUTRALIZING ANTIBODY VRC07; PRO 140; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIBODY ENGINEERING; ANTIBODY ISOLATION; ANTIVIRAL ACTIVITY; DRUG DISTRIBUTION; GENE TARGETING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PRIORITY JOURNAL; REVIEW; SINGLE DRUG DOSE; VIRUS NEUTRALIZATION; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY;

ANTIBODIES, NEUTRALIZING; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS;

EID: 84957900484     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2016.01.013     Document Type: Review

References (332)

1. [1] Johnson, S., et al. Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J. Infect. Dis. 176:5 (1997), 1215–1224.
2. [2] Malley, R., et al. Reduction of respiratory syncytial virus (RSV) in tracheal aspirates in intubated infants by use of humanized monoclonal antibody to RSV F protein. J. Infect. Dis. 178:6 (1998), 1555–1561.
3. [3] Baba, T.W., et al. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat. Med. 6:2 (2000), 200–206.
4. [4] Haigwood, N.L., et al. Passive immune globulin therapy in the SIV/macaque model: early intervention can alter disease profile. Immunol. Lett. 51:1–2 (1996), 107–114.
5. [5] Hessell, A.J., et al. Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques. Nat. Med. 15:8 (2009), 951–954.
6. [6] Hessell, A.J., et al. Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. PLoS Pathog., 5(5), 2009, e1000433.
7. [7] Hessell, A.J., et al. Broadly neutralizing monoclonal antibodies 2F5 and 4E10 directed against the human immunodeficiency virus type 1 gp41 membrane-proximal external region protect against mucosal challenge by simian-human immunodeficiency virus SHIVBa-L. J. Virol. 84:3 (2010), 1302–1313.
8. [8] Hofmann-Lehmann, R., et al. Postnatal passive immunization of neonatal macaques with a triple combination of human monoclonal antibodies against oral simian-human immunodeficiency virus challenge. J. Virol. 75:16 (2001), 7470–7480.
9. [9] Mascola, J.R., et al. Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J. Virol. 73:5 (1999), 4009–4018.
10. [10] Mascola, J.R., et al. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat. Med. 6:2 (2000), 207–210.
11. [11] Ng, C.T., et al. Passive neutralizing antibody controls SHIV viremia and enhances B cell responses in infant macaques. Nat. Med. 16:10 (2010), 1117–1119.
12. [12] Parren, P.W., et al. Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. J. Virol. 75:17 (2001), 8340–8347.
13. [13] Shibata, R., et al. Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys. Nat. Med. 5:2 (1999), 204–210.
14. [14] Trkola, A., et al. Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies. Nat. Med. 11:6 (2005), 615–622.
15. [15] Mehandru, S., et al. Adjunctive passive immunotherapy in human immunodeficiency virus type 1-infected individuals treated with antiviral therapy during acute and early infection. J. Virol. 81:20 (2007), 11016–11031.
16. [16] Caskey, M., et al. Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117. Nature 522:7557 (2015), 487–491.
17. [17] Hamel, D.J., et al. Twenty years of prospective molecular epidemiology in Senegal: changes in HIV diversity. AIDS Res. Hum. Retrovir. 23:10 (2007), 1189–1196.
18. [18] da Silva, Z.J., et al. Changes in prevalence and incidence of HIV-1, HIV-2 and dual infections in urban areas of Bissau, Guinea-Bissau: is HIV-2 disappearing?. AIDS 22:10 (2008), 1195–1202.
19. [19] Marlink, R., et al. Reduced rate of disease development after HIV-2 infection as compared to HIV-1. Science 265:5178 (1994), 1587–1590.
20. [20] Whittle, H., et al. HIV-2-infected patients survive longer than HIV-1-infected patients. AIDS 8:11 (1994), 1617–1620.
21. [21] Kanki, P.J., et al. Slower heterosexual spread of HIV-2 than HIV-1. Lancet 343:8903 (1994), 943–946.
22. [22] Duvall, M.G., et al. Maintenance of HIV-specific CD4 + T cell help distinguishes HIV-2 from HIV-1 infection. J. Immunol. 176:11 (2006), 6973–6981.
23. [23] Leligdowicz, A., et al. Direct relationship between virus load and systemic immune activation in HIV-2 infection. J. Infect. Dis. 201:1 (2010), 114–122.
24. [24] de Silva, T.I., et al. Correlates of T-cell-mediated viral control and phenotype of CD8(+) T cells in HIV-2, a naturally contained human retroviral infection. Blood 121:21 (2013), 4330–4339.
25. [25] Duvall, M.G., et al. Dendritic cells are less susceptible to human immunodeficiency virus type 2 (HIV-2) infection than to HIV-1 infection. J. Virol. 81:24 (2007), 13486–13498.
26. [26] Marchant, D., Neil, S.J., McKnight, A., Human immunodeficiency virus types 1 and 2 have different replication kinetics in human primary macrophage culture. J. Gen. Virol. 87:Pt 2 (2006), 411–418.
27. [27] MacNeil, A., et al. Direct evidence of lower viral replication rates in vivo in human immunodeficiency virus type 2 (HIV-2) infection than in HIV-1 infection. J. Virol. 81:10 (2007), 5325–5330.
28. [28] Cavaleiro, R., et al. Monocyte-mediated T cell suppression by HIV-2 envelope proteins. Eur. J. Immunol. 37:12 (2007), 3435–3444.
29. [29] Cavaleiro, R., et al. Marked immunosuppressive effects of the HIV-2 envelope protein in spite of the lower HIV-2 pathogenicity. AIDS 14:17 (2000), 2679–2686.
30. [30] Makvandi-Nejad, S., Rowland-Jones, S., How does the humoral response to HIV-2 infection differ from HIV-1 and can this explain the distinct natural history of infection with these two human retroviruses?. Immunol. Lett. 163:1 (2015), 69–75.
31. [31] Stamatatos, L., et al. Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine?. Nat. Med. 15:8 (2009), 866–870.
32. [32] Rodriguez, S.K., et al. Comparison of heterologous neutralizing antibody responses of human immunodeficiency virus type 1 (HIV-1)- and HIV-2-infected Senegalese patients: distinct patterns of breadth and magnitude distinguish HIV-1 and HIV-2 infections. J. Virol. 81:10 (2007), 5331–5338.
33. [33] Ozkaya Sahin, G., et al. Potent intratype neutralizing activity distinguishes human immunodeficiency virus type 2 (HIV-2) from HIV-1. J. Virol. 86:2 (2012), 961–971.
34. [34] de Silva, T.I., et al. Potent autologous and heterologous neutralizing antibody responses occur in HIV-2 infection across a broad range of infection outcomes. J. Virol. 86:2 (2012), 930–946.
35. [35] Bjorling, E., et al. Autologous neutralizing antibodies prevail in HIV-2 but not in HIV-1 infection. Virology 193:1 (1993), 528–530.
36. [36] Kong, R., et al. Broad and potent neutralizing antibody responses elicited in natural HIV-2 infection. J. Virol. 86:2 (2012), 947–960.
37. [37] van der Loeff, M.F., et al. Undetectable plasma viral load predicts normal survival in HIV-2-infected people in a West African village. Retrovirology, 7, 2010, 46.
38. [38] Berry, N., et al. Low peripheral blood viral HIV-2 RNA in individuals with high CD4 percentage differentiates HIV-2 from HIV-1 infection. J. Hum. Virol. 1:7 (1998), 457–468.
39. [39] Jaffar, S., et al. Rate of decline of percentage CD4 + cells is faster in HIV-1 than in HIV-2 infection. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 16:5 (1997), 327–332.
40. [40] Skar, H., et al. HIV-2 genetic evolution in patients with advanced disease is faster than that in matched HIV-1 patients. J. Virol. 84:14 (2010), 7412–7415.
41. [41] Borrego, P., et al. The role of the humoral immune response in the molecular evolution of the envelope C2, V3 and C3 regions in chronically HIV-2 infected patients. Retrovirology, 5, 2008, 78.
42. [42] Rocha, C., et al. Evolution of the human immunodeficiency virus type 2 envelope in the first years of infection is associated with the dynamics of the neutralizing antibody response. Retrovirology, 10, 2013, 110.
43. [43] Bohl, C., et al. A twin-cysteine motif in the V2 region of gp120 is associated with SIV envelope trimer stabilization. PLoS One, 8(7), 2013, e69406.
44. [44] Shi, Y., et al. Evolution of human immunodeficiency virus type 2 coreceptor usage, autologous neutralization, envelope sequence and glycosylation. J. Gen. Virol. 86:Pt 12 (2005), 3385–3396.
45. [45] Barroso, H., et al. Evolutionary and structural features of the C2, V3 and C3 envelope regions underlying the differences in HIV-1 and HIV-2 biology and infection. PLoS One, 6(1), 2011, e14548.
46. [46] Lizeng, Q., et al. Serum immunoglobulin A (IgA)-mediated immunity in human immunodeficiency virus type 2 (HIV-2) infection. Virology 308:2 (2003), 225–232.
47. [47] Ozkaya Sahin, G., et al. Frequent intratype neutralization by plasma immunoglobulin a identified in HIV type 2 infection. AIDS Res. Hum. Retrovir. 29:3 (2013), 470–478.
48. [48] Marcelino, J.M., et al. Envelope-specific antibody response in HIV-2 infection: C2V3C3-specific IgG response is associated with disease progression. AIDS 22:17 (2008), 2257–2265.
49. [49] Ackerman, M.E., et al. Polyfunctional HIV-specific antibody responses are associated with spontaneous HIV control. PLoS Pathog., 12(1), 2016, e1005315.
50. [50] Ozkaya Sahin, G., et al. Effect of complement on HIV-2 plasma antiviral activity is intratype specific and potent. J. Virol. 87:1 (2013), 273–281.
51. [51] Walker, L.M., et al. A limited number of antibody specificities mediate broad and potent serum neutralization in selected HIV-1 infected individuals. PLoS Pathog., 6(8), 2010, e1001028.
52. [52] Simek, M.D., et al. Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm. J. Virol. 83:14 (2009), 7337–7348.
53. [53] Doria-Rose, N.A., et al. Breadth of human immunodeficiency virus-specific neutralizing activity in sera: clustering analysis and association with clinical variables. J. Virol. 84:3 (2010), 1631–1636.
54. [54] Scheid, J.F., et al. Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature 458:7238 (2009), 636–640.
55. [55] Sok, D., et al. Recombinant HIV envelope trimer selects for quaternary-dependent antibodies targeting the trimer apex. Proc. Natl. Acad. Sci. U. S. A. 111:49 (2014), 17624–17629.
56. [56] Huang, J., et al. Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. Nature 491:7424 (2012), 406–412.
57. [57] Walker, L.M., et al. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 477:7365 (2011), 466–470.
58. [58] Walker, L.M., et al. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326:5950 (2009), 285–289.
59. [59] Wu, X., et al. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 329:5993 (2010), 856–861.
60. [60] Mouquet, H., et al. Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies. Proc. Natl. Acad. Sci. U. S. A. 109:47 (2012), E3268–E3277.
61. [61] Scheid, J.F., et al. Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science 333:6049 (2011), 1633–1637.
62. [62] Sok, D., et al. Promiscuous glycan site recognition by antibodies to the high-mannose patch of gp120 broadens neutralization of HIV. Sci. Transl. Med., 6(236), 2014, 236ra63.
63. [63] Doria-Rose, N.A., et al. Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies. Nature 509:7498 (2014), 55–62.
64. [64] Huang, J., et al. Broad and potent HIV-1 neutralization by a human antibody that binds the gp41-gp120 interface. Nature 515:7525 (2014), 138–142.
65. [65] Rudicell, R.S., et al. Enhanced potency of a broadly neutralizing HIV-1 antibody in vitro improves protection against lentiviral infection in vivo. J. Virol. 88:21 (2014), 12669–12682.
66. [66] Julien, J.P., et al. Asymmetric recognition of the HIV-1 trimer by broadly neutralizing antibody PG9. Proc. Natl. Acad. Sci. U. S. A. 110:11 (2013), 4351–4356.
67. [67] McLellan, J.S., et al. Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. Nature 480:7377 (2011), 336–343.
68. [68] Pancera, M., et al. Crystal structure of PG16 and chimeric dissection with somatically related PG9: structure–function analysis of two quaternary-specific antibodies that effectively neutralize HIV-1. J. Virol. 84:16 (2010), 8098–8110.
69. [69] Pancera, M., et al. Structural basis for diverse N-glycan recognition by HIV-1-neutralizing V1–V2-directed antibody PG16. Nat. Struct. Mol. Biol. 20:7 (2013), 804–813.
70. [70] Pejchal, R., et al. A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield. Science 334:6059 (2011), 1097–1103.
71. [71] Pejchal, R., et al. Structure and function of broadly reactive antibody PG16 reveal an H3 subdomain that mediates potent neutralization of HIV-1. Proc. Natl. Acad. Sci. U. S. A. 107:25 (2010), 11483–11488.
72. [72] Zhou, T., et al. Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science 329:5993 (2010), 811–817.
73. [73] Zhou, T., et al. Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature 445:7129 (2007), 732–737.
74. [74] Zhou, T., et al. Multidonor analysis reveals structural elements, genetic determinants, and maturation pathway for HIV-1 neutralization by VRC01-class antibodies. Immunity 39:2 (2013), 245–258.
75. [75] Julien, J.P., et al. Broadly neutralizing antibody PGT121 allosterically modulates CD4 binding via recognition of the HIV-1 gp120 V3 base and multiple surrounding glycans. PLoS Pathog., 9(5), 2013, e1003342.
76. [76] Ofek, G., et al. Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope. J. Virol. 78:19 (2004), 10724–10737.
77. [77] Cardoso, R.M., et al. Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp41. Immunity 22:2 (2005), 163–173.
78. [78] Julien, J.P., et al. Crystal structure of a soluble cleaved HIV-1 envelope trimer. Science 342:6165 (2013), 1477–1483.
79. [79] Lyumkis, D., et al. Cryo-EM structure of a fully glycosylated soluble cleaved HIV-1 envelope trimer. Science 342:6165 (2013), 1484–1490.
80. [80] Bartesaghi, A., et al. Prefusion structure of trimeric HIV-1 envelope glycoprotein determined by cryo-electron microscopy. Nat. Struct. Mol. Biol. 20:12 (2013), 1352–1357.
81. [81] Pancera, M., et al. Structure and immune recognition of trimeric pre-fusion HIV-1 Env. Nature 514:7523 (2014), 455–461.
82. [82] Hoxie, J.A., Toward an antibody-based HIV-1 vaccine. Annu. Rev. Med. 61 (2010), 135–152.
83. [83] McElrath, M.J., Haynes, B.F., Induction of immunity to human immunodeficiency virus type-1 by vaccination. Immunity 33:4 (2010), 542–554.
84. [84] Yoon, H., et al. CATNAP: a tool to compile, analyze and tally neutralizing antibody panels. Nucleic Acids Res. 43:W1 (2015), W213–W219.
85. [85] Eroshkin, A.M., et al. bNAber: database of broadly neutralizing HIV antibodies. Nucleic Acids Res. 42:Database issue (2014), D1133–D1139.
86. [86] Wibmer, C.K., Moore, P.L., Morris, L., HIV broadly neutralizing antibody targets. Curr. Opin. HIV AIDS 10:3 (2015), 135–143.
87. [87] Kwong, P.D., Mascola, J.R., Nabel, G.J., Broadly neutralizing antibodies and the search for an HIV-1 vaccine: the end of the beginning. Nat. Rev. Immunol. 13:9 (2013), 693–701.
88. [88] West, A.P. Jr., et al. Structural insights on the role of antibodies in HIV-1 vaccine and therapy. Cell 156:4 (2014), 633–648.
89. [89] Klein, F., et al. Somatic mutations of the immunoglobulin framework are generally required for broad and potent HIV-1 neutralization. Cell 153:1 (2013), 126–138.
90. [90] Corti, D., et al. Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals. PLoS One, 5(1), 2010, e8805.
91. [91] Wu, X., et al. Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. Science 333:6049 (2011), 1593–1602.
92. [92] Xiao, X., et al. Maturation pathways of cross-reactive HIV-1 neutralizing antibodies. Viruses 1:3 (2009), 802–817.
93. [93] Kepler, T.B., et al. Immunoglobulin gene insertions and deletions in the affinity maturation of HIV-1 broadly reactive neutralizing antibodies. Cell Host Microbe 16:3 (2014), 304–313.
94. [94] Kaul, R., et al. Mucosal IgA in exposed, uninfected subjects: evidence for a role in protection against HIV infection. AIDS 15:3 (2001), 431–432.
95. [95] Hirbod, T., et al. HIV acquisition is associated with increased antimicrobial peptides and reduced HIV neutralizing IgA in the foreskin prepuce of uncircumcised men. PLoS Pathog., 10(10), 2014, e1004416.
96. [96] Seaton, K.E., et al. HIV-1 specific IgA detected in vaginal secretions of HIV uninfected women participating in a microbicide trial in Southern Africa are primarily directed toward gp120 and gp140 specificities. PLoS One, 9(7), 2014, e101863.
97. [97] Shacklett, B.L., Understanding the “lucky few”: the conundrum of HIV-exposed, seronegative individuals. Curr. HIV/AIDS Rep. 3:1 (2006), 26–31.
98. [98] Dickover, R., et al. Role of maternal autologous neutralizing antibody in selective perinatal transmission of human immunodeficiency virus type 1 escape variants. J. Virol. 80:13 (2006), 6525–6533.
99. [99] Permar, S.R., et al. Maternal HIV-1 envelope-specific antibody responses and reduced risk of perinatal transmission. J. Clin. Invest. 125:7 (2015), 2702–2706.
100. [100] Goo, L., et al. Neutralizing antibody escape during HIV-1 mother-to-child transmission involves conformational masking of distal epitopes in envelope. J. Virol. 86:18 (2012), 9566–9582.
101. [101] Rainwater, S.M., et al. Cloning and characterization of functional subtype A HIV-1 envelope variants transmitted through breastfeeding. Curr. HIV Res. 5:2 (2007), 189–197.
102. [102] Wu, X., et al. Neutralization escape variants of human immunodeficiency virus type 1 are transmitted from mother to infant. J. Virol. 80:2 (2006), 835–844.
103. [103] Hidajat, R., et al. Correlation of vaccine-elicited systemic and mucosal nonneutralizing antibody activities with reduced acute viremia following intrarectal simian immunodeficiency virus SIVmac251 challenge of rhesus macaques. J. Virol. 83:2 (2009), 791–801.
104. [104] Gomez-Roman, V.R., et al. Vaccine-elicited antibodies mediate antibody-dependent cellular cytotoxicity correlated with significantly reduced acute viremia in rhesus macaques challenged with SIVmac251. J. Immunol. 174:4 (2005), 2185–2189.
105. [105] Barouch, D.H., et al. HIV-1 vaccines. Protective efficacy of adenovirus/protein vaccines against SIV challenges in rhesus monkeys. Science 349:6245 (2015), 320–324.
106. [106] Barouch, D.H., et al. Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys. Nature 503:7475 (2013), 224–228.
107. [107] Fouts, T.R., et al. Balance of cellular and humoral immunity determines the level of protection by HIV vaccines in rhesus macaque models of HIV infection. Proc. Natl. Acad. Sci. U. S. A. 112:9 (2015), E992–E999.
108. [108] Bonsignori, M., et al. Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family. J. Virol. 86:21 (2012), 11521–11532.
109. [109] Forthal, D.N., et al. Recombinant gp120 vaccine-induced antibodies inhibit clinical strains of HIV-1 in the presence of Fc receptor-bearing effector cells and correlate inversely with HIV infection rate. J. Immunol. 178:10 (2007), 6596–6603.
110. [110] Haynes, B.F., et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N. Engl. J. Med. 366:14 (2012), 1275–1286.
111. [111] Shingai, M., et al. Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaques. J. Exp. Med. 211:10 (2014), 2061–2074.
112. [112] Fouda, G.G., et al. Postnatally-transmitted HIV-1 envelope variants have similar neutralization-sensitivity and function to that of nontransmitted breast milk variants. Retrovirology, 10, 2013, 3.
113. [113] Mabuka, J., et al. HIV-1 maternal and infant variants show similar sensitivity to broadly neutralizing antibodies, but sensitivity varies by subtype. AIDS 27:10 (2013), 1535–1544.
114. [114] Nakamura, K.J., et al. Coverage of primary mother-to-child HIV transmission isolates by second-generation broadly neutralizing antibodies. AIDS 27:3 (2013), 337–346.
115. [115] Ackerman, M.E., et al. Enhanced phagocytic activity of HIV-specific antibodies correlates with natural production of immunoglobulins with skewed affinity for FcgammaR2a and FcgammaR2b. J. Virol. 87:10 (2013), 5468–5476.
116. [116] Banerjee, K., et al. IgG subclass profiles in infected HIV type 1 controllers and chronic progressors and in uninfected recipients of env vaccines. AIDS Res. Hum. Retrovir. 26:4 (2010), 445–458.
117. [117] Lambotte, O., et al. Heterogeneous neutralizing antibody and antibody-dependent cell cytotoxicity responses in HIV-1 elite controllers. AIDS 23:8 (2009), 897–906.
118. [118] Shingai, M., et al. Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia. Nature 503:7475 (2013), 277–280.
119. [119] Horwitz, J.A., et al. HIV-1 suppression and durable control by combining single broadly neutralizing antibodies and antiretroviral drugs in humanized mice. Proc. Natl. Acad. Sci. U. S. A. 110:41 (2013), 16538–16543.
120. [120] Balazs, A.B., et al. Antibody-based protection against HIV infection by vectored immunoprophylaxis. Nature 481:7379 (2012), 81–84.
121. [121] Gauduin, M.C., et al. Passive immunization with a human monoclonal antibody protects hu-PBL-SCID mice against challenge by primary isolates of HIV-1. Nat. Med. 3:12 (1997), 1389–1393.
122. [122] Parren, P.W., et al. Protection against HIV-1 infection in hu-PBL-SCID mice by passive immunization with a neutralizing human monoclonal antibody against the gp120 CD4-binding site. AIDS 9:6 (1995), F1–F6.
123. [123] Veselinovic, M., et al. Topical gel formulation of broadly neutralizing anti-HIV-1 monoclonal antibody VRC01 confers protection against HIV-1 vaginal challenge in a humanized mouse model. Virology 432:2 (2012), 505–510.
124. [124] Ledgerwood, J.E., et al. Safety, pharmacokinetics and neutralization of the broadly neutralizing HIV-1 human monoclonal antibody VRC01 in healthy adults. Clin. Exp. Immunol. 182:3 (2015), 289–301.
125. [125] Klein, F., et al. HIV therapy by a combination of broadly neutralizing antibodies in humanized mice. Nature 492:7427 (2012), 118–122.
126. [126] Pelegrin, M., Naranjo-Gomez, M., Piechaczyk, M., Antiviral monoclonal antibodies: can they be more than simple neutralizing agents?. Trends Microbiol. 23:10 (2015), 653–665.
127. [127] Haigwood, N.L., et al. Passive immunotherapy in simian immunodeficiency virus-infected macaques accelerates the development of neutralizing antibodies. J. Virol. 78:11 (2004), 5983–5995.
128. [128] Jaworski, J.P., et al. Neutralizing polyclonal IgG present during acute infection prevents rapid disease onset in simian-human immunodeficiency virus SHIVSF162P3-infected infant rhesus macaques. J. Virol. 87:19 (2013), 10447–10459.
129. [129] Yamamoto, H., et al. Post-infection immunodeficiency virus control by neutralizing antibodies. PLoS One, 2(6), 2007, e540.
130. [130] Klein, F., et al. Enhanced HIV-1 immunotherapy by commonly arising antibodies that target virus escape variants. J. Exp. Med. 211:12 (2014), 2361–2372.
131. [131] Dey, B., Berger, E.A., Towards an HIV cure based on targeted killing of infected cells: different approaches against acute versus chronic infection. Curr. Opin. HIV AIDS 10:3 (2015), 207–213.
132. [132] Levy, J.A., Not an HIV cure, but encouraging new directions. N. Engl. J. Med. 360:7 (2009), 724–725.
133. [133] Euler, Z., Alter, G., Exploring the potential of monoclonal antibody therapeutics for HIV-1 eradication. AIDS Res. Hum. Retrovir. 31:1 (2015), 13–24.
134. [134] Deal, C.E., Balazs, A.B., Vectored antibody gene delivery for the prevention or treatment of HIV infection. Curr. Opin. HIV AIDS 10:3 (2015), 190–197.
135. [135] Checkley, M.A., Luttge, B.G., Freed, E.O., HIV-1 envelope glycoprotein biosynthesis, trafficking, and incorporation. J. Mol. Biol. 410:4 (2011), 582–608.
136. [136] Svicher, V., et al. Understanding HIV compartments and reservoirs. Curr. HIV/AIDS Rep. 11:2 (2014), 186–194.
137. [137] McCoy, L.E., et al. Incomplete neutralization and deviation from sigmoidal neutralization curves for HIV broadly neutralizing monoclonal antibodies. PLoS Pathog., 11(8), 2015, e1005110.
138. [138] Sievers, S.A., et al. Antibody engineering for increased potency, breadth and half-life. Curr. Opin. HIV AIDS 10:3 (2015), 151–159.
139. [139] Yang, W.P., et al. CDR walking mutagenesis for the affinity maturation of a potent human anti-HIV-1 antibody into the picomolar range. J. Mol. Biol. 254:3 (1995), 392–403.
140. [140] Barbas, C.F. 3rd, et al. In vitro evolution of a neutralizing human antibody to human immunodeficiency virus type 1 to enhance affinity and broaden strain cross-reactivity. Proc. Natl. Acad. Sci. U. S. A. 91:9 (1994), 3809–3813.
141. [141] Zhang, M.Y., et al. Improved breadth and potency of an HIV-1-neutralizing human single-chain antibody by random mutagenesis and sequential antigen panning. J. Mol. Biol. 335:1 (2004), 209–219.
142. [142] Willis, J.R., et al. Redesigned HIV antibodies exhibit enhanced neutralizing potency and breadth. J. Clin. Invest. 125:6 (2015), 2523–2531.
143. [143] Diskin, R., et al. Increasing the potency and breadth of an HIV antibody by using structure-based rational design. Science 334:6060 (2011), 1289–1293.
144. [144] Diskin, R., et al. Restricting HIV-1 pathways for escape using rationally designed anti-HIV-1 antibodies. J. Exp. Med. 210:6 (2013), 1235–1249.
145. [145] Chen, J., et al. Mechanism of HIV-1 neutralization by antibodies targeting a membrane-proximal region of gp41. J. Virol. 88:2 (2014), 1249–1258.
146. [146] Georgiev, I.S., et al. Antibodies VRC01 and 10E8 neutralize HIV-1 with high breadth and potency even with Ig-framework regions substantially reverted to germline. J. Immunol. 192:3 (2014), 1100–1106.
147. [147] Fletcher, C.V., et al. Nonlinear pharmacokinetics of high-dose recombinant fusion protein CD4-IgG2 (PRO 542) observed in HIV-1-infected children. J. Allergy Clin. Immunol. 119:3 (2007), 747–750.
148. [148] Hussey, R.E., et al. A soluble CD4 protein selectively inhibits HIV replication and syncytium formation. Nature 331:6151 (1988), 78–81.
149. [149] Jacobson, J.M., et al. Single-dose safety, pharmacology, and antiviral activity of the human immunodeficiency virus (HIV) type 1 entry inhibitor PRO 542 in HIV-infected adults. J. Infect. dis. 182:1 (2000), 326–329.
150. [150] Haim, H., et al. Soluble CD4 and CD4-mimetic compounds inhibit HIV-1 infection by induction of a short-lived activated state. PLoS Pathog., 5(4), 2009, e1000360.
151. [151] Moebius, U., et al. The human immunodeficiency virus gp120 binding site on CD4: delineation by quantitative equilibrium and kinetic binding studies of mutants in conjunction with a high-resolution CD4 atomic structure. J. Exp. Med. 176:2 (1992), 507–517.
152. [152] Sullivan, N., et al. Determinants of human immunodeficiency virus type 1 envelope glycoprotein activation by soluble CD4 and monoclonal antibodies. J. Virol. 72:8 (1998), 6332–6338.
153. [153] Jacobson, J.M., et al. Treatment of advanced human immunodeficiency virus type 1 disease with the viral entry inhibitor PRO 542. Antimicrob. Agents Chemother. 48:2 (2004), 423–429.
154. [154] Gardner, M.R., et al. AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges. Nature 519:7541 (2015), 87–91.
155. [155] West, A.P. Jr., et al. Structural basis for germ-line gene usage of a potent class of antibodies targeting the CD4-binding site of HIV-1 gp120. Proc. Natl. Acad. Sci. U. S. A. 109:30 (2012), E2083–E2090.
156. [156] Kong, R., et al. Improving neutralization potency and breadth by combining broadly reactive HIV-1 antibodies targeting major neutralization epitopes. J. Virol. 89:5 (2015), 2659–2671.
157. [157] Mascola, J.R., et al. Potent and synergistic neutralization of human immunodeficiency virus (HIV) type 1 primary isolates by hyperimmune anti-HIV immunoglobulin combined with monoclonal antibodies 2F5 and 2G12. J. Virol. 71:10 (1997), 7198–7206.
158. [158] Zwick, M.B., et al. Neutralization synergy of human immunodeficiency virus type 1 primary isolates by cocktails of broadly neutralizing antibodies. J. Virol. 75:24 (2001), 12198–12208.
159. [159] Pace, C., Markowitz, M., Monoclonal antibodies to host cellular receptors for the treatment and prevention of HIV-1 infection. Curr. Opin. HIV AIDS 10:3 (2015), 144–150.
160. [160] Perez-Jimenez, R., et al. Probing the effect of force on HIV-1 receptor CD4. ACS Nano 8:10 (2014), 10313–10320.
161. [161] Pace, C.S., et al. Anti-CD4 monoclonal antibody ibalizumab exhibits breadth and potency against HIV-1, with natural resistance mediated by the loss of a V5 glycan in envelope. J. Acquir. Immune Defic. Syndr. 62:1 (2013), 1–9.
162. [162] Toma, J., et al. Loss of asparagine-linked glycosylation sites in variable region 5 of human immunodeficiency virus type 1 envelope is associated with resistance to CD4 antibody ibalizumab. J. Virol. 85:8 (2011), 3872–3880.
163. [163] Trkola, A., et al. Potent, broad-spectrum inhibition of human immunodeficiency virus type 1 by the CCR5 monoclonal antibody PRO 140. J. Virol. 75:2 (2001), 579–588.
164. [164] Pugach, P., et al. Neutralizing antibody and anti-retroviral drug sensitivities of HIV-1 isolates resistant to small molecule CCR5 inhibitors. Virology 377:2 (2008), 401–407.
165. [165] Jacobson, J.M., et al. Anti-HIV-1 activity of weekly or biweekly treatment with subcutaneous PRO 140, a CCR5 monoclonal antibody. J. Infect. Dis. 201:10 (2010), 1481–1487.
166. [166] Jacobson, J.M., et al. Antiviral activity of single-dose PRO 140, a CCR5 monoclonal antibody, in HIV-infected adults. J. Infect. Dis. 198:9 (2008), 1345–1352.
167. [167] Pace, C.S., et al. Bispecific antibodies directed to CD4 domain 2 and HIV envelope exhibit exceptional breadth and picomolar potency against HIV-1. Proc. Natl. Acad. Sci. U. S. A. 110:33 (2013), 13540–13545.
168. [168] Schanzer, J., et al. Development of tetravalent, bispecific CCR5 antibodies with antiviral activity against CCR5 monoclonal antibody-resistant HIV-1 strains. Antimicrob. Agents Chemother. 55:5 (2011), 2369–2378.
169. [169] Zandman-Goddard, G., Shoenfeld, Y., HIV and autoimmunity. Autoimmun. Rev. 1:6 (2002), 329–337.
170. [170] Kopelman, R.G., Zolla-Pazner, S., Association of human immunodeficiency virus infection and autoimmune phenomena. Am. J. Med. 84:1 (1988), 82–88.
171. [171] Solinger, A.M., et al. Acquired immune deficiency syndrome (AIDS) and autoimmunity-mutually exclusive entities?. J. Clin. Immunol. 8:1 (1988), 32–42.
172. [172] Liu, M., et al. Polyreactivity and autoreactivity among HIV-1 antibodies. J. Virol. 89:1 (2015), 784–798.
173. [173] Wu, H., et al. Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract. J. Mol. Biol. 368:3 (2007), 652–665.
174. [174] Pepinsky, R.B., et al. Improving the solubility of anti-LINGO-1 monoclonal antibody Li33 by isotype switching and targeted mutagenesis. Protein Sci. 19:5 (2010), 954–966.
175. [175] Hotzel, I., et al. A strategy for risk mitigation of antibodies with fast clearance. MAbs 4:6 (2012), 753–760.
176. [176] Kwon, Y.D., et al. Enhancing the solubility of HIV-1 neutralizing antibody 10E8. AIDS Res. Hum. Retrovir., 30(Suppl. 1), 2014.
177. [177] Boesch, A.W., Brown, E.P., Ackerman, M.E., The role of Fc receptors in HIV prevention and therapy. Immunol. Rev. 268:1 (2015), 296–310.
178. [178] Boesch, A.W., Alter, G., Ackerman, M.E., Prospects for engineering HIV-specific antibodies for enhanced effector function and half-life. Curr. Opin. HIV AIDS 10:3 (2015), 160–169.
179. [179] Nimmerjahn, F., A constant threat for HIV: Fc-engineering to enhance broadly neutralizing antibody activity for immunotherapy of the acquired immunodeficiency syndrome. Eur. J. Immunol. 45:8 (2015), 2183–2190.
180. [180] Roopenian, D.C., Akilesh, S., FcRn: the neonatal Fc receptor comes of age. Nat. Rev. Immunol. 7:9 (2007), 715–725.
181. [181] Ko, S.Y., et al. Enhanced neonatal Fc receptor function improves protection against primate SHIV infection. Nature 514:7524 (2014), 642–645.
182. [182] Gupta, S., et al. The Neonatal Fc receptor (FcRn) enhances human immunodeficiency virus type 1 (HIV-1) transcytosis across epithelial cells. PLoS Pathog., 9(11), 2013, e1003776.
183. [183] Weflen, A.W., et al. Multivalent immune complexes divert FcRn to lysosomes by exclusion from recycling sorting tubules. Mol. Biol. Cell 24:15 (2013), 2398–2405.
184. [184] Hinton, P.R., et al. An engineered human IgG1 antibody with longer serum half-life. J. Immunol. 176:1 (2006), 346–356.
185. [185] Vaccaro, C., et al. Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels. Nat. Biotechnol. 23:10 (2005), 1283–1288.
186. [186] Dall'Acqua, W.F., Kiener, P.A., Wu, H., Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn). J. Biol. Chem. 281:33 (2006), 23514–23524.
187. [187] Kim, J.K., et al. Mapping the site on human IgG for binding of the MHC class I-related receptor, FcRn. Eur. J. Immunol. 29:9 (1999), 2819–2825.
188. [188] West, A.P. Jr., Bjorkman, P.J., Crystal structure and immunoglobulin G binding properties of the human major histocompatibility complex-related Fc receptor(,). Biochemistry 39:32 (2000), 9698–9708.
189. [189] Grevys, A., et al. Fc engineering of human IgG1 for altered binding to the neonatal Fc receptor affects Fc effector functions. J. Immunol. 194:11 (2015), 5497–5508.
190. [190] Monnet, C., et al. Combined glyco- and protein-Fc engineering simultaneously enhance cytotoxicity and half-life of a therapeutic antibody. mAbs 6:2 (2014), 422–436.
191. [191] Zhou, M., Ruprecht, R.M., Are anti-HIV IgAs good guys or bad guys?. Retrovirology, 11, 2014, 109.
192. [192] Watkins, J.D., et al. Anti-HIV IgA isotypes: differential virion capture and inhibition of transcytosis are linked to prevention of mucosal R5 SHIV transmission. AIDS 27:9 (2013), F13–F20.
193. [193] Sholukh, A.M., et al. Defense-in-depth by mucosally administered anti-HIV dimeric IgA2 and systemic IgG1 mAbs: complete protection of rhesus monkeys from mucosal SHIV challenge. Vaccine 33:17 (2015), 2086–2095.
194. [194] Stieh, D.J., et al. Aggregate complexes of HIV-1 induced by multimeric antibodies. Retrovirology, 11, 2014, 78.
195. [195] Fahrbach, K.M., et al. Differential binding of IgG and IgA to mucus of the female reproductive tract. PLoS One, 8(10), 2013, e76176.
196. [196] Hur, E.M., et al. Inhibitory effect of HIV-specific neutralizing IgA on mucosal transmission of HIV in humanized mice. Blood 120:23 (2012), 4571–4582.
197. [197] Brunke, C., et al. Effect of a tail piece cysteine deletion on biochemical and functional properties of an epidermal growth factor receptor-directed IgA2m(1) antibody. MAbs 5:6 (2013), 936–945.
198. [198] Lohse, S., et al. Recombinant dimeric IgA antibodies against the epidermal growth factor receptor mediate effective tumor cell killing. J. Immunol. 186:6 (2011), 3770–3778.
199. [199] Moldt, B., et al. Simplifying the synthesis of SIgA: combination of dIgA and rhSC using affinity chromatography. Methods 65:1 (2014), 127–132.
200. [200] Lohse, S., et al. Characterization of a mutated IgA2 antibody of the m(1) allotype against the epidermal growth factor receptor for the recruitment of monocytes and macrophages. J. Biol. Chem. 287:30 (2012), 25139–25150.
201. [201] Wright, A., Lamm, M.E., Huang, Y.T., Excretion of human immunodeficiency virus type 1 through polarized epithelium by immunoglobulin A. J. Virol. 82:23 (2008), 11526–11535.
202. [202] Milligan, C., et al. Passively acquired antibody-dependent cellular cytotoxicity (ADCC) activity in HIV-infected infants is associated with reduced mortality. Cell Host Microbe 17:4 (2015), 500–506.
203. [203] Ahmad, R., et al. Evidence for a correlation between antibody-dependent cellular cytotoxicity-mediating anti-HIV-1 antibodies and prognostic predictors of HIV infection. J. Clin. Immunol. 21:3 (2001), 227–233.
204. [204] Baum, L.L., et al. HIV-1 gp120-specific antibody-dependent cell-mediated cytotoxicity correlates with rate of disease progression. J. Immunol. 157:5 (1996), 2168–2173.
205. [205] Forthal, D.N., et al. Antibody-dependent cellular cytotoxicity independently predicts survival in severely immunocompromised human immunodeficiency virus-infected patients. J. Infect. Dis. 180:4 (1999), 1338–1341.
206. [206] Forthal, D.N., Landucci, G., Keenan, B., Relationship between antibody-dependent cellular cytotoxicity, plasma HIV type 1 RNA, and CD4 + lymphocyte count. AIDS Res. Hum. Retrovir. 17:6 (2001), 553–561.
207. [207] Forthal, D.N., et al. FcgammaRIIa genotype predicts progression of HIV infection. J. Immunol. 179:11 (2007), 7916–7923.
208. [208] French, M.A., et al. Vaccine-induced IgG2 anti-HIV p24 is associated with control of HIV in patients with a ‘high-affinity’ FcgammaRIIa genotype. AIDS 24:13 (2010), 1983–1990.
209. [209] Ngo-Giang-Huong, N., et al. HIV type 1-specific IgG2 antibodies: markers of helper T cell type 1 response and prognostic marker of long-term nonprogression. AIDS Res. Hum. Retrovir. 17:15 (2001), 1435–1446.
210. [210] Ackerman, M.E., Dugast, A.S., Alter, G., Emerging concepts on the role of innate immunity in the prevention and control of HIV infection. Annu. Rev. Med. 63 (2012), 113–130.
211. [211] Huber, M., et al. Complement lysis activity in autologous plasma is associated with lower viral loads during the acute phase of HIV-1 infection. PLoS Med., 3(11), 2006, e441.
212. [212] Aasa-Chapman, M.M., et al. Detection of antibody-dependent complement-mediated inactivation of both autologous and heterologous virus in primary human immunodeficiency virus type 1 infection. J. Virol. 79:5 (2005), 2823–2830.
213. [213] Moog, C., et al. Protective effect of vaginal application of neutralizing and nonneutralizing inhibitory antibodies against vaginal SHIV challenge in macaques. Mucosal Immunol. 7:1 (2014), 46–56.
214. [214] Bournazos, S., et al. Broadly neutralizing anti-HIV-1 antibodies require Fc effector functions for in vivo activity. Cell 158:6 (2014), 1243–1253.
215. [215] Nimmerjahn, F., Ravetch, J.V., Translating basic mechanisms of IgG effector activity into next generation cancer therapies. Cancer Immun., 12, 2012, 13.
216. [216] Nimmerjahn, F., Ravetch, J.V., Divergent immunoglobulin g subclass activity through selective Fc receptor binding. Science 310:5753 (2005), 1510–1512.
217. [217] Gilbert, P., et al. Magnitude and breadth of a nonprotective neutralizing antibody response in an efficacy trial of a candidate HIV-1 gp120 vaccine. J. Infect. Dis. 202:4 (2010), 595–605.
218. [218] Jones, N.G., et al. AIDSVAX immunization induces HIV-specific CD8 + T-cell responses in high-risk, HIV-negative volunteers who subsequently acquire HIV infection. Vaccine 27:7 (2009), 1136–1140.
219. [219] Rerks-Ngarm, S., et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med. 361:23 (2009), 2209–2220.
220. [220] Chung, A.W., et al. Polyfunctional Fc-effector profiles mediated by IgG subclass selection distinguish RV144 and VAX003 vaccines. Sci. Transl. Med. 6:228 (2014), 228–238.
221. [221] Kellner, C., et al. Boosting ADCC and CDC activity by Fc engineering and evaluation of antibody effector functions. Methods 65:1 (2014), 105–113.
222. [222] Lazar, G.A., et al. Engineered antibody Fc variants with enhanced effector function. Proc. Natl. Acad. Sci. U. S. A. 103:11 (2006), 4005–4010.
223. [223] Li, F., Ravetch, J.V., Inhibitory Fcgamma receptor engagement drives adjuvant and anti-tumor activities of agonistic CD40 antibodies. Science 333:6045 (2011), 1030–1034.
224. [224] Forthal, D.N., et al. Fc-glycosylation influences Fcgamma receptor binding and cell-mediated anti-HIV activity of monoclonal antibody 2G12. J. Immunol. 185:11 (2010), 6876–6882.
225. [225] Forthal, D.N., et al. IgG2 inhibits HIV-1 internalization by monocytes, and IgG subclass binding is affected by gp120 glycosylation. AIDS 25:17 (2011), 2099–2104.
226. [226] Lai, J.I., et al. Divergent antibody subclass and specificity profiles but not protective HLA-B alleles are associated with variable antibody effector function among HIV-1 controllers. J. Virol. 88:5 (2014), 2799–2809.
227. [227] Perez, L.G., Zolla-Pazner, S., Montefiori, D.C., Antibody-dependent, FcgammaRI-mediated neutralization of HIV-1 in TZM-bl cells occurs independently of phagocytosis. J. Virol. 87:9 (2013), 5287–5290.
228. [228] Ackerman, M.E., et al. Natural variation in Fc glycosylation of HIV-specific antibodies impacts antiviral activity. J. Clin. Invest. 123:5 (2013), 2183–2192.
229. [229] Halper-Stromberg, A., et al. Broadly neutralizing antibodies and viral inducers decrease rebound from HIV-1 latent reservoirs in humanized mice. Cell 158:5 (2014), 989–999.
230. [230] Hessell, A.J., et al. Fc receptor but not complement binding is important in antibody protection against HIV. Nature 449:7158 (2007), 101–104.
231. [231] Shields, R.L., et al. High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. J. Biol. Chem. 276:9 (2001), 6591–6604.
232. [232] Bowles, J.A., et al. Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab. Blood 108:8 (2006), 2648–2654.
233. [233] Stavenhagen, J.B., et al. Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcgamma receptors. Cancer Res. 67:18 (2007), 8882–8890.
234. [234] Zalevsky, J., et al. The impact of Fc engineering on an anti-CD19 antibody: increased Fcgamma receptor affinity enhances B-cell clearing in nonhuman primates. Blood 113:16 (2009), 3735–3743.
235. [235] Liu, Z., et al. Asymmetrical Fc engineering greatly enhances antibody-dependent cellular cytotoxicity (ADCC) effector function and stability of the modified antibodies. J. Biol. Chem. 289:6 (2014), 3571–3590.
236. [236] Indik, Z., et al. Human Fc gamma RII, in the absence of other Fc gamma receptors, mediates a phagocytic signal. J. Clin. Invest. 88:5 (1991), 1766–1771.
237. [237] Richards, J.O., et al. Optimization of antibody binding to FcgammaRIIa enhances macrophage phagocytosis of tumor cells. Mol. Cancer Ther. 7:8 (2008), 2517–2527.
238. [238] Painter, R.H., The C1q receptor site on human immunoglobulin G. Can. J. Biochem. Cell Biol. 62:6 (1984), 418–425.
239. [239] Idusogie, E.E., et al. Engineered antibodies with increased activity to recruit complement. J. Immunol. 166:4 (2001), 2571–2575.
240. [240] Moore, G.L., et al. Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functions. MAbs 2:2 (2010), 181–189.
241. [241] Natsume, A., et al. Engineered antibodies of IgG1/IgG3 mixed isotype with enhanced cytotoxic activities. Cancer Res. 68:10 (2008), 3863–3872.
242. [242] Kelton, W., et al. IgGA: a “cross-isotype” engineered human Fc antibody domain that displays both IgG-like and IgA-like effector functions. Chem. Biol. 21:12 (2014), 1603–1609.
243. [243] Diebolder, C.A., et al. Complement is activated by IgG hexamers assembled at the cell surface. Science 343:6176 (2014), 1260–1263.
244. [244] Lux, A., Nimmerjahn, F., Impact of differential glycosylation on IgG activity. Adv. Exp. Med. Biol. 780 (2011), 113–124.
245. [245] Shields, R.L., et al. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity. J. Biol. Chem. 277:30 (2002), 26733–26740.
246. [246] Anthony, R.M., Ravetch, J.V., A novel role for the IgG Fc glycan: the anti-inflammatory activity of sialylated IgG Fcs. J. Clin. Immunol. 30:Suppl. 1 (2010), S9–14.
247. [247] Boyd, P.N., Lines, A.C., Patel, A.K., The effect of the removal of sialic acid, galactose and total carbohydrate on the functional activity of Campath-1H. Mol. Immunol. 32:17–18 (1995), 1311–1318.
248. [248] Lund, J., et al. Oligosaccharide-protein interactions in IgG antibody molecules: structural and functional consequences. Biochem. Soc. Trans., 23(1), 1995, 102S.
249. [249] Tsuchiya, N., et al. Effects of galactose depletion from oligosaccharide chains on immunological activities of human IgG. J. Rheumatol. 16:3 (1989), 285–290.
250. [250] Karsten, C.M., et al. Anti-inflammatory activity of IgG1 mediated by Fc galactosylation and association of FcgammaRIIB and dectin-1. Nat. Med. 18:9 (2012), 1401–1406.
251. [251] Jefferis, R., Glycosylation as a strategy to improve antibody-based therapeutics. Nat. Rev. Drug Discov. 8:3 (2009), 226–234.
252. [252] Shinkawa, T., et al. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J. Biol. Chem. 278:5 (2003), 3466–3473.
253. [253] Naso, M.F., et al. Engineering host cell lines to reduce terminal sialylation of secreted antibodies. mAbs 2:5 (2010), 519–527.
254. [254] Loos, A., Steinkellner, H., IgG-Fc glycoengineering in non-mammalian expression hosts. Arch. Biochem. Biophys. 526:2 (2012), 167–173.
255. [255] Yin, B., et al. Glycoengineering of Chinese hamster ovary cells for enhanced erythropoietin N-glycan branching and sialylation. Biotechnol. Bioeng. 112:11 (2015), 2343–2351.
256. [256] Hodoniczky, J., Zheng, Y.Z., James, D.C., Control of recombinant monoclonal antibody effector functions by Fc N-glycan remodeling in vitro. Biotechnol. Prog. 21:6 (2005), 1644–1652.
257. [257] Huang, W., et al. Chemoenzymatic glycoengineering of intact IgG antibodies for gain of functions. J. Am. Chem. Soc. 134:29 (2012), 12308–12318.
258. [258] Moldt, B., et al. A nonfucosylated variant of the anti-HIV-1 monoclonal antibody b12 has enhanced FcgammaRIIIa-mediated antiviral activity in vitro but does not improve protection against mucosal SHIV challenge in macaques. J. Virol. 86:11 (2012), 6189–6196.
259. [259] Sazinsky, S.L., et al. Aglycosylated immunoglobulin G1 variants productively engage activating Fc receptors. Proc. Natl. Acad. Sci. U. S. A. 105:51 (2008), 20167–20172.
260. [260] Jung, S.T., et al. Aglycosylated IgG variants expressed in bacteria that selectively bind FcgammaRI potentiate tumor cell killing by monocyte-dendritic cells. Proc. Natl. Acad. Sci. U. S. A. 107:2 (2010), 604–609.
261. [261] Repp, R., et al. Combined Fc-protein- and Fc-glyco-engineering of scFv-Fc fusion proteins synergistically enhances CD16a binding but does not further enhance NK-cell mediated ADCC. J. Immunol. Methods 373:1–2 (2011), 67–78.
262. [262] Masuda, K., et al. Enhanced binding affinity for FcgammaRIIIa of fucose-negative antibody is sufficient to induce maximal antibody-dependent cellular cytotoxicity. Mol. Immunol. 44:12 (2007), 3122–3131.
263. [263] Yu, X., et al. Engineering hydrophobic protein–carbohydrate interactions to fine-tune monoclonal antibodies. J. Am. Chem. Soc. 135:26 (2013), 9723–9732.
264. [264] Lacek, K., et al. Dramatic potentiation of the antiviral activity of HIV antibodies by cholesterol conjugation. J. Biol. Chem. 289:50 (2014), 35015–35028.
265. [265] Gavrilyuk, J., et al. Antibody conjugation approach enhances breadth and potency of neutralization of anti-HIV-1 antibodies and CD4-IgG. J. Virol. 87:9 (2013), 4985–4993.
266. [266] Dey, B., Del Castillo, C.S., Berger, E.A., Neutralization of human immunodeficiency virus type 1 by sCD4-17b, a single-chain chimeric protein, based on sequential interaction of gp120 with CD4 and coreceptor. J. Virol. 77:5 (2003), 2859–2865.
267. [267] West, A.P. Jr., et al. Evaluation of CD4-CD4i antibody architectures yields potent, broadly cross-reactive anti-human immunodeficiency virus reagents. J. Virol. 84:1 (2010), 261–269.
268. [268] Chen, W., et al. Exceptionally potent and broadly cross-reactive, bispecific multivalent HIV-1 inhibitors based on single human CD4 and antibody domains. J. Virol. 88:2 (2014), 1125–1139.
269. [269] Bera, T.K., et al. Specific killing of HIV-infected lymphocytes by a recombinant immunotoxin directed against the HIV-1 envelope glycoprotein. Mol. Med. 4:6 (1998), 384–391.
270. [270] Kennedy, P.E., et al. Anti-HIV-1 immunotoxin 3B3(Fv)-PE38: enhanced potency against clinical isolates in human PBMCs and macrophages, and negligible hepatotoxicity in macaques. J. Leukoc. Biol. 80:5 (2006), 1175–1182.
271. [271] Denton, P.W., et al. Targeted cytotoxic therapy kills persisting HIV infected cells during ART. PLoS Pathog., 10(1), 2014, e1003872.
272. [272] Klein, J.S., Bjorkman, P.J., Few and far between: how HIV may be evading antibody avidity. PLoS Pathog., 6(5), 2010, e1000908.
273. [273] Galimidi, R.P., et al. Intra-spike crosslinking overcomes antibody evasion by HIV-1. Cell 160:3 (2015), 433–446.
274. [274] Schaefer, W., et al. Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies. Proc. Natl. Acad. Sci. U. S. A. 108:27 (2011), 11187–11192.
275. [275] Asokan, M., et al. Bispecific antibodies targeting different epitopes on the HIV-1 envelope exhibit broad and potent neutralization. J. Virol., 2015.
276. [276] Ho, D.D., Y. Huang, and J. Yu, Improved hiv-1-neutralizing antibody potency and breadth via cell receptor anchoring using bispecific antibodies with native architecture. 2015, Google Patents.
277. [277] Craig, R.B., et al. Anti-HIV double variable domain immunoglobulins binding both gp41 and gp120 for targeted delivery of immunoconjugates. PLoS One, 7(10), 2012, e46778.
278. [278] Mouquet, H., et al. Enhanced HIV-1 neutralization by antibody heteroligation. Proc. Natl. Acad. Sci. U. S. A. 109:3 (2012), 875–880.
279. [279] Rinaldo, C., et al. High levels of anti-human immunodeficiency virus type 1 (HIV-1) memory cytotoxic T-lymphocyte activity and low viral load are associated with lack of disease in HIV-1-infected long-term nonprogressors. J. Virol. 69:9 (1995), 5838–5842.
280. [280] Klein, M.R., et al. Kinetics of Gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: a longitudinal analysis of rapid progressors and long-term asymptomatics. J. Exp. Med. 181:4 (1995), 1365–1372.
281. [281] Pinto, L.A., et al. ENV-specific cytotoxic T lymphocyte responses in HIV seronegative health care workers occupationally exposed to HIV-contaminated body fluids. J. Clin. Invest. 96:2 (1995), 867–876.
282. [282] Stieglmaier, J., Benjamin, J., Nagorsen, D., Utilizing the BiTE (bispecific T-cell engager) platform for immunotherapy of cancer. Expert. Opin. Biol. Ther. 15:8 (2015), 1093–1099.
283. [283] Berg, J., et al. Bispecific antibodies that mediate killing of cells infected with human immunodeficiency virus of any strain. Proc. Natl. Acad. Sci. U. S. A. 88:11 (1991), 4723–4727.
284. [284] Traunecker, A., Lanzavecchia, A., Karjalainen, K., Bispecific single chain molecules (Janusins) target cytotoxic lymphocytes on HIV infected cells. EMBO J. 10:12 (1991), 3655–3659.
285. [285] Chamow, S.M., et al. A humanized, bispecific immunoadhesin-antibody that retargets CD3 + effectors to kill HIV-1-infected cells. J. Immunol. 153:9 (1994), 4268–4280.
286. [286] Fernandez-Sesma, A., et al. Superantigen-activated T cells redirected by a bispecific antibody inhibit vesicular stomatitis virus replication in vitro and in vivo. J. Immunol. 160:4 (1998), 1841–1849.
287. [287] Sung, J.A., et al. Dual-affinity re-targeting proteins direct T cell-mediated cytolysis of latently HIV-infected cells. J. Clin. Invest. 125:11 (2015), 4077–4090.
288. [288] Pegu, A., et al. Activation and lysis of human CD4 cells latently infected with HIV-1. Nat. Commun., 6, 2015, 8447.
289. [289] Kochenderfer, J.N., et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood 116:20 (2010), 4099–4102.
290. [290] Maude, S.L., et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl. J. Med. 371:16 (2014), 1507–1517.
291. [291] Porter, D.L., et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci. Transl. Med., 7(303), 2015, 303ra139.
292. [292] Frey, N.V., Porter, D.L., CAR T-cells merge into the fast lane of cancer care. Am. J. Hematol., 2015.
293. [293] Lam, S., Bollard, C., T-cell therapies for HIV. Immunotherapy 5:4 (2013), 407–414.
294. [294] Zhen, A., Kitchen, S., Stem-cell-based gene therapy for HIV infection. Viruses 6:1 (2013), 1–12.
295. [295] Qasim, W., et al. First clinical application of Talen engineered universal CAR19 T cells in B-ALL. 57th American Society of Hematology (ASH) Annual Meeting, 2015 (Orlando, FL).
296. [296] Roberts, M.R., et al. Targeting of human immunodeficiency virus-infected cells by CD8 + T lymphocytes armed with universal T-cell receptors. Blood 84:9 (1994), 2878–2889.
297. [297] Sahu, G.K., et al. Anti-HIV designer T cells progressively eradicate a latently infected cell line by sequentially inducing HIV reactivation then killing the newly gp120-positive cells. Virology 446:1–2 (2013), 268–275.
298. [298] Romeo, C., Seed, B., Cellular immunity to HIV activated by CD4 fused to T cell or Fc receptor polypeptides. Cell 64:5 (1991), 1037–1046.
299. [299] Masiero, S., et al. T-cell engineering by a chimeric T-cell receptor with antibody-type specificity for the HIV-1 gp120. Gene Ther. 12:4 (2005), 299–310.
300. [300] Liu, L., et al. Novel CD4-based bispecific chimeric antigen receptor designed for enhanced anti-HIV potency and absence of HIV entry receptor activity. J. Virol. 89:13 (2015), 6685–6694.
301. [301] Scholler, J., et al. Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells. Sci. Transl. Med., 4(132), 2012, 132ra53.
302. [302] Mitsuyasu, R.T., et al. Prolonged survival and tissue trafficking following adoptive transfer of CD4zeta gene-modified autologous CD4(+) and CD8(+) T cells in human immunodeficiency virus-infected subjects. Blood 96:3 (2000), 785–793.
303. [303] Deeks, S.G., et al. A phase II randomized study of HIV-specific T-cell gene therapy in subjects with undetectable plasma viremia on combination antiretroviral therapy. Mol. Ther. 5:6 (2002), 788–797.
304. [304] Hombach, A.A., Holzinger, A., Abken, H., The weal and woe of costimulation in the adoptive therapy of cancer with chimeric antigen receptor (CAR)-redirected T cells. Curr. Mol. Med. 13:7 (2013), 1079–1088.
305. [305] Ni, Z., et al. Expression of chimeric receptor CD4zeta by natural killer cells derived from human pluripotent stem cells improves in vitro activity but does not enhance suppression of HIV infection in vivo. Stem Cells 32:4 (2014), 1021–1031.
306. [306] Joseph, A., et al. Inhibition of in vivo HIV infection in humanized mice by gene therapy of human hematopoietic stem cells with a lentiviral vector encoding a broadly neutralizing anti-HIV antibody. J. Virol. 84:13 (2010), 6645–6653.
307. [307] Luo, X.M., et al. Engineering human hematopoietic stem/progenitor cells to produce a broadly neutralizing anti-HIV antibody after in vitro maturation to human B lymphocytes. Blood 113:7 (2009), 1422–1431.
308. [308] Abdool, K.S., Abdool, K.Q., Baxter, C., Antibodies for HIV prevention in young women. Curr. Opin. HIV AIDS 10:3 (2015), 183–189.
309. [309] Gengiah, T.N., et al. Adherence challenges with drugs for pre-exposure prophylaxis to prevent HIV infection. Int. J. Clin. Pharm. 36:1 (2014), 70–85.
310. [310] Saunders, K.O., et al. Sustained delivery of a broadly neutralizing antibody in nonhuman primates confers long-term protection against simian/human immunodeficiency virus infection. J. Virol. 89:11 (2015), 5895–5903.
311. [311] Thurman, A.R., et al. Intravaginal rings as delivery systems for microbicides and multipurpose prevention technologies. Int. J. Womens Health 5 (2013), 695–708.
312. [312] Gunawardana, M., et al. An intravaginal ring for the sustained delivery of antibodies. J. Pharm. Sci. 103:11 (2014), 3611–3620.
313. [313] Mitragotri, S., Burke, P.A., Langer, R., Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies. Nat. Rev. Drug Discov. 13:9 (2014), 655–672.
314. [314] Muthumani, K., et al. Optimized and enhanced DNA plasmid vector based in vivo construction of a neutralizing anti-HIV-1 envelope glycoprotein fab. Hum. Vaccin. Immunother. 9:10 (2013), 2253–2262.
315. [315] Nowrouzi, A., et al. Integration frequency and intermolecular recombination of rAAV vectors in non-human primate skeletal muscle and liver. Mol. Ther. 20:6 (2012), 1177–1186.
316. [316] Penaud-Budloo, M., et al. Adeno-associated virus vector genomes persist as episomal chromatin in primate muscle. J. Virol. 82:16 (2008), 7875–7885.
317. [317] Schnepp, B.C., et al. Genetic fate of recombinant adeno-associated virus vector genomes in muscle. J. Virol. 77:6 (2003), 3495–3504.
318. [318] Jiang, H., et al. Evidence of multiyear factor IX expression by AAV-mediated gene transfer to skeletal muscle in an individual with severe hemophilia B. Mol. Ther. 14:3 (2006), 452–455.
319. [319] Yla-Herttuala, S., Endgame: glybera finally recommended for approval as the first gene therapy drug in the European union. Mol. Ther. 20:10 (2012), 1831–1832.
320. [320] Schnepp, B.C., Johnson, P.R., Adeno-associated virus delivery of broadly neutralizing antibodies. Curr. Opin. HIV AIDS 9:3 (2014), 250–256.
321. [321] Lewis, A.D., et al. Generation of neutralizing activity against human immunodeficiency virus type 1 in serum by antibody gene transfer. J. Virol. 76:17 (2002), 8769–8775.
322. [322] Fang, J., et al. Stable antibody expression at therapeutic levels using the 2 A peptide. Nat. Biotechnol. 23:5 (2005), 584–590.
323. [323] Johnson, P.R., et al. Vector-mediated gene transfer engenders long-lived neutralizing activity and protection against SIV infection in monkeys. Nat. Med. 15:8 (2009), 901–906.
324. [324] Fang, J., et al. An antibody delivery system for regulated expression of therapeutic levels of monoclonal antibodies in vivo. Mol. Ther. 15:6 (2007), 1153–1159.
325. [325] Balazs, A.B., et al. Vectored immunoprophylaxis protects humanized mice from mucosal HIV transmission. Nat. Med. 20:3 (2014), 296–300.
326. [326] Saunders, K.O., et al. Broadly neutralizing human immunodeficiency virus type 1 antibody gene transfer protects nonhuman primates from mucosal simian-human immunodeficiency virus infection. J. Virol. 89:16 (2015), 8334–8345.
327. [327] Fuchs, S.P., et al. AAV-delivered antibody mediates significant protective effects against SIVmac239 challenge in the absence of neutralizing activity. PLoS Pathog., 11(8), 2015, e1005090.
328. [328] Wang, L., et al. Impact of pre-existing immunity on gene transfer to nonhuman primate liver with adeno-associated virus 8 vectors. Hum. Gene Ther. 22:11 (2011), 1389–1401.
329. [329] Martinez-Navio, J.M., et al. Host anti-antibody responses following adeno-associated virus-mediated delivery of antibodies against HIV and SIV in Rhesus monkeys. Mol. Ther., 2015.
330. [330] Joos, B., et al. Long-term multiple-dose pharmacokinetics of human monoclonal antibodies (MAbs) against human immunodeficiency virus type 1 envelope gp120 (MAb 2G12) and gp41 (MAbs 4E10 and 2F5). Antimicrob. Agents Chemother. 50:5 (2006), 1773–1779.
331. [331] Foley, B., Leitner, T., Apetrei, C., Hahn, B., Mizrachi, I., Mullins, J., Rambaut, A., Wolinsky, S., Korber, B., HIV Sequence Compendium. 2014, Theoretical Biology and Biophysics Group: Los Alamos National Laboratory, NM, LA-UR, 13–26007.
332. [332] Pettersen, E.F., et al. UCSF Chimera—a visualization system for exploratory research and analysis. J. Comput. Chem. 25:13 (2004), 1605–1612.